Myasthenia Gravis - A Pipeline Analysis Report
- Published: Jun 2018
- Pages: 121
- SKU: IRTNTR23176
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for myasthenia gravis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.
Overview of the drug development for myasthenia gravis
Myasthenia gravis is one of the most common neurological disorders causing weakness in the skeleton muscles. It is likely to happen more when the connection between the muscles and the nerve cells become impaired. Both genetic and immunological abnormalities at the neuromuscular junctions (NMJ) are the common cause for myasthenia gravis. At present, there is no cure for the disease, but it can be treated well with long-term medications. One of the key symptoms of myasthenia gravis is weakness, mainly in the muscles that are under the voluntary control of an individual. It can worsen if not treated on time. For people with myasthenia gravis, it is difficult to swallow, and the neck and limb muscles become weak. Myasthenia gravis is a disorder of neuromuscular transmission, resulting from the binding of autoantibodies to the components of NMJs, most commonly the acetocholine receptor (AChR). Technavio’s market research analysts suggest that rising incidences of myasthenia gravis is expected to boost the drug development for myasthenia gravis.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of myasthenia gravis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development for the treatment of myasthenia gravis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
Therapeutic assessment of the drug development for myasthenia gravis by route of administration
The intravenous route of administration (ROA) involves the application of the drug directly administered through veins, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development for myasthenia gravis by therapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for myasthenia gravis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for myasthenia gravis?
- What are the companies that are currently involved in the drug development for myasthenia gravis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.